Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.70 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.70 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234428 | 0.95 | DDB1 (0.72) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL22848677 | 0.91 | CRBN (0.68) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL20442798 | 0.90 | DDB1 (0.69) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL20325482 | 0.89 | DDB1 (0.73) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL28909815 | 0.89 | DDB1 (0.68) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL30805411 | 0.88 | CRBN (0.66) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL24420973 | 0.88 | CRBN (0.71) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL29614567 | 0.88 | CRBN (0.71) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL31444687 | 0.87 | CRBN (0.62) | DDB1CRBNGPR119STAT3 | |
| SCHEMBL20442568 | 0.87 | GPR119 (0.67) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024152247-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS , INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024054625-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |